Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Kleiman, Laura B ^a   Krebs, Angela M ^a,b   Kim, Stephen Y ^a   Hong, Theodore S ^a   Haigis, Kevin M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APITOLISIB; AZD 8931; BARASERTIB; BUPARLISIB; CHIR 265; DACTOLISIB; DOVITINIB; FLUOROURACIL; GEFITINIB; K RAS PROTEIN; LUMINESPIB; MIDOSTAURIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PALBOCICLIB; PERIFOSINE; PICTILISIB; SELUMETINIB; SORAFENIB; SUNITINIB; TRAMETINIB; VELIPARIB; VEMURAFENIB; ENZYME INHIBITOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RADIOSENSITIZING AGENT; RAS PROTEIN;

ADVANCED CANCER; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FOLLOW UP; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IONIZING RADIATION; PROTEIN EXPRESSION; RADIOSENSITIZATION; RECTUM CANCER; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHEMORADIOTHERAPY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; RECTAL NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; CHEMORADIOTHERAPY; ENZYME INHIBITORS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RADIATION-SENSITIZING AGENTS; RAS PROTEINS; RECTAL NEOPLASMS;

EID: 84892610542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082982     Document Type: Article

References (55)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi:10.1002/ijc.25516. PubMed: 21351269.
2. Eng C (2010) The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist 15: 73-84. doi:10.1634/theoncologist.2010-S1-73. PubMed: 20067946.
3. Aklilu M, Eng C (2011) The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 8: 649-659. doi:10.1038/nrclinonc.2011.118. PubMed: 21826084.
4. Debucquoy A, Machiels JP, McBride WH, Haustermans K (2010) Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. Clin Cancer Res 16: 2709-2714. doi: 10.1158/1078-0432.CCR-09-1622. PubMed: 20427690.
5. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ et al. (1994) Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344: 707-711. doi:10.1016/S0140-6736(94)92206-3. PubMed: 7915774.
6. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V et al. (2006) Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 93: 1115-1122. doi: 10.1002/bjs.5349. PubMed: 16804870.
7. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B et al. (2005) Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23: 5644-5650. doi:10.1200/JCO.2005.08.144. PubMed: 16110023.
8. Hong TS, Clark JW, Haigis KM (2012) Cancers of the colon and rectum: identical or fraternal twins? Cancer Discov 2: 117-121. Available online at: doi:10.1158/2159-8290.CD-11-0315 PubMed: 22585856.
9. Bosset JF, Collette L, Calais G, Mineur L, Maingon P et al. (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355: 1114-1123. doi:10.1056/NEJMoa060829. PubMed: 16971718.
10. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M et al. (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696. doi: 10.1200/JCO.2005.02.1329. PubMed: 16246976.
11. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D et al. (2000) Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 60: 6597-6600. PubMed: 11118040.
12. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL et al. (2005) Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 65: 8433-8441. doi: 10.1158/0008-5472.CAN-05-0158. PubMed: 16166322.
13. Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB et al. (2007) Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 9: 341-348. doi: 10.1593/neo.06823. PubMed: 17460778.
14. Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD (2002) Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62: 4142-4150. PubMed: 12124353.
15. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ et al. (2001) The Ras radiation resistance pathway. Cancer Res 61: 4278-4282. PubMed: 11358856.
16. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ (2003) The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22: 5866-5875. doi:10.1038/sj.onc.1206699. PubMed: 12947393.
17. Minjgee M, Toulany M, Kehlbach R, Giehl K, Rodemann HP (2011) KRAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys 81: 1506-1514. doi:10.1016/j.ijrobp.2011.05.057. PubMed: 21985943.
18. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD et al. (2011) Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg 254: 483-492; discussion: 21865946.
19. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774. doi:10.1038/nrc3106. PubMed: 21993244.
20. Ma CX, Janetka JW, Piwnica-Worms H (2011) Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17: 88-96. doi:10.1016/j.molmed.2010.10.009. PubMed: 21087899.
21. Eriksson D, Stigbrand T (2010) Radiation-induced cell death mechanisms. Tumour Biol 31: 363-372. doi:10.1007/s13277-010-0042-8. PubMed: 20490962.
22. Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11: 239-253. doi: 10.1038/nrc3007. PubMed: 21430696.
23. Elshaikh M, Ljungman M, Ten Haken R, Lichter AS (2006) Advances in radiation oncology. Annu Rev Med 57: 19-31. doi:10.1146/annurev.med.57.121304. 131431. PubMed: 16409134.
24. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA et al. (2010) Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational. DNA Repair - Cancer Res 70: 4972-4981.
25. Vance S, Liu E, Zhao L, Parsels JD, Parsels LA et al. (2011) Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 10: 4321-4329. doi: 10.4161/cc.10.24.18661. PubMed: 22134241.
26. Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16: 376-383. doi: 10.1158/1078-0432.CCR-09-1029. PubMed: 20068082.
27. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S et al. (2004) Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 24: 708-718. doi:10.1128/MCB.24.2.708-718.2004. PubMed: 14701743.
28. Chen T, Stephens PA, Middleton FK, Curtin NJ (2012) Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today 17: 194-202. doi:10.1016/j.drudis.2011.12.009. PubMed: 22192883.
29. Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW et al. (2006) Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J 25: 3179-3190. doi:10.1038/sj.emboj.7601209. PubMed: 16794575.
30. Leung-Pineda V, Ryan CE, Piwnica-Worms H (2006) Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 26: 7529-7538. doi:10.1128/MCB.00447-06. PubMed: 17015476.
31. Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C et al. (2005) Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 25: 3553-3562. doi:10.1128/MCB.25.9.3553-3562.2005. PubMed: 15831461.
32. Carlessi L, Buscemi G, Fontanella E, Delia D (2010) A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage. Biochim Biophys Acta 1803: 1213-1223. doi:10.1016/j.bbamcr.2010.06.002. PubMed: 20599567.
33. Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC et al. (2005) Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 19: 607-618. doi:10.1016/j.molcel.2005.07.019. PubMed: 16137618.
34. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM et al. (2010) Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 16: 4532-4542. doi: 10.1158/1078-0432.CCR-10-0523. PubMed: 20823146.
35. Maugeri-Saccà M, Bartucci M, De Maria R (2013) Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev 39: 525-533. doi:10.1016/j.ctrv.2012.10.007. PubMed: 23207059.
36. Fokas E, Im JH, Hill S, Yameen S, Stratford M et al. (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72: 239-248. doi: 10.1158/0008-5472. CAN-11-2263. PubMed: 22108822.
37. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS et al. (2009) Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 69: 7644-7652. doi:10.1158/0008- 5472.CAN-09-0823. PubMed: 19789349.
38. Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N et al. (2012) The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14: 34-43. PubMed: 22355272.
39. Azad A, Jackson S, Cullinane C, Natoli A, Neilsen PM et al. (2011) Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res 9: 1696-1707. doi:10.1158/1541- 7786.MCR-11-0312. PubMed: 22009179.
40. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A et al. (2011) Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17: 2373-2384. doi:10.1158/1078-0432.CCR-10-2289. PubMed: 21372221.
41. Ma Z, Yao G, Zhou B, Fan Y, Gao S et al. (2012) The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. Mol Med Report 6: 897-903
42. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D et al. (2010) In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 16: 2076-2084. doi:10.1158/1078-0432.CCR-09-3277. PubMed: 20233881.
43. Yang H, Yoon SJ, Jin J, Choi SH, Seol HJ et al. (2011) Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun 406: 53-58. doi:10.1016/j.bbrc.2011.01.106. PubMed: 21291864.
44. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S et al. (2010) Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 9: 995-1004. doi:10.4161/cc.9.5.10935. PubMed: 20160494.
45. Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J (2006) The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 5: 1983-1988. doi:10.4161/cc.5.17.3184. PubMed: 16931916.
46. Xiao Z, Xue J, Sowin TJ, Zhang H (2006) Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 5: 1935-1943. doi:10.1158/1535-7163.MCT-06- 0077. PubMed: 16928813.
47. Anderson VE, Walton MI, Eve PD, Boxall KJ, Antoni L et al. (2011) CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res 71: 463-472. doi: 10.1158/1538-7445.AM2011-463. PubMed: 21239475.
48. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ et al. (2007) Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6: 935-944. doi:10.1158/1535-7163. MCT-06-0567. PubMed: 17363488.
49. Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J et al. (2009) Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}- amide]. J Pharmacol Exp Ther 331: 816-826. doi:10.1124/jpet.109.154997. PubMed: 19741151.
50. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H (2005) A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24: 1403-1411. doi:10.1038/sj.onc.1208309. PubMed: 15608676.
51. Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L et al. (2011) Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 17: 3706-3715. doi: 10.1158/1078-0432.CCR-10-3082. PubMed: 21482692.
52. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7: 2955-2966. doi:10.1158/1535-7163.MCT-08-0492. PubMed: 18790776.
53. Vitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12: 385-392. doi:10.1038/nrg2956. PubMed: 21527953.
54. Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D et al. (2004) The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23: 4353-4361. doi:10.1038/sj.onc.1207573. PubMed: 15048074.
55. Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N et al. (2005) Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 280: 39246-39252. doi:10.1074/jbc.M505009200. PubMed: 16159883.